Northwest Biotherapeutics (LTS:0K95) EV-to-Revenue : 428.52 (As of May. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Northwest Biotherapeutics's enterprise value is £455.51 Mil. Northwest Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was £1.06 Mil. Therefore, Northwest Biotherapeutics's EV-to-Revenue for today is 428.52.

The historical rank and industry rank for Northwest Biotherapeutics's EV-to-Revenue or its related term are showing as below:

LTS:0K95' s EV-to-Revenue Range Over the Past 10 Years
Min: 33.9 Med: 301.6 Max: 1504.69
Current: 432.78

During the past 13 years, the highest EV-to-Revenue of Northwest Biotherapeutics was 1504.69. The lowest was 33.90. And the median was 301.60.

LTS:0K95's EV-to-Revenue is ranked worse than
91.72% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs LTS:0K95: 432.78

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Northwest Biotherapeutics's stock price is £2.40. Northwest Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was £0.00. Therefore, Northwest Biotherapeutics's PS Ratio for today is .

Northwest Biotherapeutics EV-to-Revenue Historical Data

The historical data trend for Northwest Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics EV-to-Revenue Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

60.86

987.62

683.23

509.48

448.98

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															325.05	351.79	514.89	448.98	499.24

Competitive Comparison of Northwest Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Northwest Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's EV-to-Revenue falls into.

Northwest Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Northwest Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	455.513	/	1.063
	=	428.52

Northwest Biotherapeutics's current Enterprise Value is £455.51 Mil.
Northwest Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £1.06 Mil.

Northwest Biotherapeutics (LTS:0K95) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Northwest Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.40	/	0
	=

Northwest Biotherapeutics's share price for today is £2.40.
Northwest Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.00.

Northwest Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines